Prostate MRI AI
AI-powered prostate cancer detection, segmentation, and reporting that saves 15-25 minutes per case.
Key Features
Series Auto-Detection
Automatically identifies and populates biparametric series (T2, ADC, High B-value DWI) from any scanner vendor.
AI Segmentation
Whole prostate and transition zone contouring with 92% Dice score vs expert contours. Robust to motion artifacts.
Lesion Detection
Automated suspicious lesion identification with PI-RADS scoring assistance and confidence intervals.
Fusion Biopsy Export
Direct export to Philips Navigo and other MRI/US fusion biopsy systems via Rois.xml and DICOM formats.
Image-as-Biomarker
Extract prognostic data from imaging already being performed -- tumor volume, ADC values, texture features.
Auto-Windowing
Optimizes lesion visualization based on published best practices for biparametric MRI.
The Problem
Prostate cancer is the second most common cancer in men worldwide, with 1.4 million new cases diagnosed annually. MRI has become the standard of care for detection, but PI-RADS scoring variability between radiologists ranges from 40-60% inter-reader agreement. Incumbent AI solutions require expensive licenses and on-premise hardware. We want to change that.
Our Approach
Acurix Prostate AI is cloud-native — no local GPU hardware, no IT installation projects. Upload a study from any browser and receive AI-assisted analysis in minutes.
The workflow is designed by a radiologist for radiologists. Series auto-detection eliminates manual series selection. Auto-windowing ensures optimal lesion visualization. AI segmentation provides 3D contours with minimal manual editing.
Image-as-Biomarker
The patient is already getting an MRI. Our platform extracts prognostic biomarkers from that same imaging data — tumor volume, ADC statistics, texture features — potentially replacing expensive blood-based tests like 4Kscore ($500-800 per test).
Pricing
Contact us for pricing. Cloud-native architecture enables dramatically lower costs than incumbent solutions.